EGFR Signaling in Colorectal Cancer Metastasis: Molecular Mechanisms and Targeted Therapeutic Strategies

Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide, with metastatic colorectal cancer (mCRC) accounting for most CRC-associated deaths. Despite advances in systemic therapy, mCRC remains associated with poor prognosis because of its molecular heterogeneity, metastatic potential, and the emergence of therapeutic resistance. Improved understanding of the molecular landscape of mCRC has enabled biomarker-driven treatment strategies that have advanced precision oncology. Among the key signaling pathways involved in mCRC, the epidermal growth factor receptor (EGFR) pathway plays a central role in tumor progression and metastasis. EGFR activation triggers the RAS-RAF-MEK-ERK (rat sarcoma-rapidly accelerated fibrosarcoma-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase) and PI3K-AKT-mTOR (phosphoinositide 3-kinase–protein kinase B–mechanistic target of rapamycin) signaling cascades, promoting cellular proliferation, survival, migration, invasion, angiogenesis, and therapeutic resistance. Genetic alterations involving KRAS (kirsten rat sarcoma viral oncogene homolog), NRAS (neuroblastoma rat sarcoma viral oncogene homolog), BRAF (B-Raf proto-oncogene, serine/threonine kinase), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), HER2 (human epidermal growth factor receptor 2), and PTEN (phosphatase and tensin homolog) frequently dysregulate these pathways and serve as predictive biomarkers for targeted therapy. Anti-EGFR monoclonal antibodies have transformed the treatment landscape of mCRC. However, their clinical benefit is frequently limited by intrinsic and acquired resistance mechanisms driven by molecular alterations, pathway redundancy, compensatory signaling, and tumor heterogeneity. This review examines the role of EGFR signaling in CRC metastasis, the molecular alterations affecting EGFR-associated pathways, and the evolving landscape of EGFR-directed and pathway-focused targeted therapies in mCRC.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-18
DOI
https://doi.org/10.3390/ijms272210346
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

EGFR Signaling in Colorectal Cancer Metastasis: Molecular Mechanisms and Targeted Therapeutic Strategies

Mridula Krishnan, Premila Devi Leiphrakpam, Senthil Jagannathan Rajappa, Chandrakanth Are et al.
1 links
International Journal of Molecular Sciences
Colorectal Cancer Treatments and Studies
article

EGFR Signaling in Colorectal Cancer Metastasis: Molecular Mechanisms and Targeted Therapeutic Strategies

Mridula Krishnan, Premila Devi Leiphrakpam, Senthil Jagannathan Rajappa, Chandrakanth Are, Rishi Batra
article en

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide, with metastatic colorectal cancer (mCRC) accounting for most CRC-associated deaths. Despite advances in systemic therapy, mCRC remains associated with poor prognosis because of its molecular heterogeneity, metastatic potential, and the emergence of therapeutic resistance. Improved understanding of the molecular landscape of mCRC has enabled biomarker-driven treatment strategies that have advanced precision oncology. Among the key signaling pathways involved in mCRC, the epidermal growth factor receptor (EGFR) pathway plays a central role in tumor progression and metastasis. EGFR activation triggers the RAS-RAF-MEK-ERK (rat sarcoma-rapidly accelerated fibrosarcoma-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase) and PI3K-AKT-mTOR (phosphoinositide 3-kinase–protein kinase B–mechanistic target of rapamycin) signaling cascades, promoting cellular proliferation, survival, migration, invasion, angiogenesis, and therapeutic resistance. Genetic alterations involving KRAS (kirsten rat sarcoma viral oncogene homolog), NRAS (neuroblastoma rat sarcoma viral oncogene homolog), BRAF (B-Raf proto-oncogene, serine/threonine kinase), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), HER2 (human epidermal growth factor receptor 2), and PTEN (phosphatase and tensin homolog) frequently dysregulate these pathways and serve as predictive biomarkers for targeted therapy. Anti-EGFR monoclonal antibodies have transformed the treatment landscape of mCRC. However, their clinical benefit is frequently limited by intrinsic and acquired resistance mechanisms driven by molecular alterations, pathway redundancy, compensatory signaling, and tumor heterogeneity. This review examines the role of EGFR signaling in CRC metastasis, the molecular alterations affecting EGFR-associated pathways, and the evolving landscape of EGFR-directed and pathway-focused targeted therapies in mCRC.

International Journal of Molecular SciencesVol. 27(22)
Basavatarakam Indo American Cancer Hospital and Research Institute (IN), Cancer Hospital and Research Institute (IN), University of Nebraska Medical Center (US)
Good health and well-being
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon